ANTX
NASDAQ · Pharmaceuticals
An2 Therapeutics Inc
$4.00
+0.09 (+2.30%)
Financial Highlights (FY 2025)
Revenue
8.24M
Net Income
1.80M
Gross Margin
64.0%
Profit Margin
21.9%
Rev Growth
-4.4%
D/E Ratio
1.44
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 64.0% | 64.0% | 64.0% |
| Operating Margin | 27.8% | 27.2% | 27.8% |
| Profit Margin | 21.9% | 22.7% | 22.3% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 8.24M | 7.98M | 7.65M |
| Gross Profit | 5.27M | 5.11M | 4.90M |
| Operating Income | 2.29M | 2.17M | 2.13M |
| Net Income | 1.80M | 1.81M | 1.71M |
| Gross Margin | 64.0% | 64.0% | 64.0% |
| Operating Margin | 27.8% | 27.2% | 27.8% |
| Profit Margin | 21.9% | 22.7% | 22.3% |
| Rev Growth | -4.4% | +17.2% | +22.3% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 12.13M | 12.55M | 11.92M |
| Total Equity | 8.40M | 9.18M | 9.24M |
| D/E Ratio | 1.44 | 1.37 | 1.29 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 3.67M | 3.33M | 3.32M |
| Free Cash Flow | 1.39M | 970.9K | 896.1K |